StockWatch
·
PRIVI SPECIALITY CHEMICALS LTD · QQ2 FY-2027 · THE CALL

Record PAT but revenue growth trailing 20% target

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsPRIVISCLPrivi Speciality Chemicals Ltd03 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Met profitability targets (EBITDA margin 27.48% vs 25%); beat prior PAT guidance (₹117 Cr). Missed revenue growth guidance (12% actual vs 20% target).

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong execution on profitability (PAT +30%, EBITDA margin 27.48% beats 25% target) and capacity expansion (Phase-1 complete). But revenue growth of 12% YoY and H1 at ~15% trails the reaffirmed 20% guidance, leaving H2 with a steep 25%+ growth requirement. Phase-2 ramp delayed to H2 FY28; regulatory approvals on Fine Sciences merger pending.

₹760.5 Cr

Revenue · +12% YoY

₹117.5 Cr

Reported PAT · +30.3% YoY

Expanding

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Record quarterly revenue and profitability

OVERSTATED

₹760.5 Cr revenue (+12% YoY), ₹117.5 Cr PAT (+30.3% YoY) — record PAT, but revenue growth lags 20% target

Maintain 20% growth guidance overall in coming years

MISS

H1 FY27 grew ~15% (implied from statement), Q2 at 12% YoY — trajectory shows 20% FY27 exit requires H2 at 25%+

EBITDA margin 27.48% as against 26.12% prior H1

OVERSTATED

OPM delivered 26.3%; EBITDA of ₹212.49 Cr claimed, but structured analysis shows ~₹200 Cr — benefited by ₹1.62 Cr state incentives

Phase-1 expansion (48K→54K MT) completed by Sep 2026

MET

Confirmed completed; ramp-up 85–90% utilization expected in Q4 FY27 when new contracts start

20% or beating 20% confidence for FY27-28

MISS

Based on H1 miss (15%), guidance math is tight; Phase-2 revenue only starts H2 FY28, not FY27

Earnings quality

What changed since the last call

Deltas vs. the prior call

Phase-1 expansion status

Upgrade

Was delayed to Sep 2026 in prior call; now completed on schedule as of Sep 30. Ramp to 85–90% utilization in Q4.

EBITDA margin guidance

Upgrade

Prior guidance: sustain ~25%. Delivered: 27.48% in Q2 FY27. Structural improvement from cost discipline and higher-value product mix.

Revenue growth track

Downgrade

Guided 20% growth; H1 at ~15%, Q2 at +12% YoY. Analysts pushed back (Ram Arvind, iThoughtPMS) on math to hit 20% exit. Management defended seasonality but no new numeric proof.

Fine Sciences merger timeline

Withdrawn

Prior target: ₹100 Cr revenue by FY25. Actual FY26: ₹68 Cr. Now awaiting regulatory approvals with vague 'next FY' completion guidance. Target not reset publicly.

JV revenue contribution

New

JV turned profitable in Q2 FY27 (₹28 Cr revenue). Now guiding ₹225 Cr for FY27-28 and Phase-3 pilot studies underway.

The Q&A

Firm analyst pushback on 20% guidance. Ram Arvind (iThoughtPMS) directly challenged math: H1 at 15% growth would require H2 at 25%+ to hit 20% FY27. Narayan reaffirmed guidance citing seasonal patterns (H2 stronger) but did not provide forward-looking order book or volume drivers. Overall, management held the line on guidance despite visible skepticism.

The exchanges that mattered

Phase-1 debottlenecking ramp — Krish Salot, Veer Growth AIF

Answered

Expansion completed. Part coming in Q3, significant part in Q4. Expect 85–90% capacity utilization in Q4 for expanded capacity.

20% revenue growth guidance — Ram Arvind, iThoughtPMS

Partial

Still maintain 20% guidance. First half normally lower, second half stronger. Annual basis you look at us; very confident 20% annual.

Growth segment drivers — Ram Arvind, iThoughtPMS

Dodged

Do not give segmental guidance. But overall, will maintain 20% growth.

Raw material and freight pressure — Mahima Gidwani, PhillipCapital PMS

Answered

2/3 revenue from non-petroleum sources, ~70% resilient. Freight: learned from past mistakes; now quarterly pricing mechanism with customers. Not faced extent of disturbance others face.

CST and GTO sourcing concentration — Divesh Chainani, Equentis

Partial

Very diversified sourcing.

JV revenue guidance — Divesh Chainani, Equentis

Answered

2 phases of expansion; one underway. Expect ₹225 Cr revenue. Also 3rd phase pilot studies underway.

Capex plan and revenue roadmap — Anirudh Sharma, Ekaant Investments

Answered

Phase-1 completed ₹450 Cr. Phase 2 and 3 expect ₹1,000 Cr capex. 3 phases combined potential ₹1,700–1,800 Cr revenue. By 2030, should hit ₹5,000 Cr.

Fine Sciences merger status — Krish Salot, Veer Growth AIF

Partial

Fine Sciences at ₹68 Cr FY26. 5 products, 4 already supplied to multinationals. Regulatory approvals pending. Next year significant improvement expected.

Working capital improvement — Nikhil Porwal, Perpetual Capital

Answered

Definitely this time. Long-term, expect 105–110 days broadly.

Other income drivers — Nirav Gandhi, Sunidhi Securities

Answered

Exports high, dollar in favor. Net exporter, helps. Other income consists major part FX gains.

State incentive receipt timeline — Sudhir Bheda, Bheda Family Office

Answered

H1 received ₹1.62 Cr (vs ₹9 Cr prior year). Expect more in next 6 months. Range ₹12–15 Cr total expected.

FY27-28 guidance — Sudhir Bheda, Bheda Family Office

Partial

Positive outlook. Confident maintaining 20% or beating 20%. Close to ₹4,000 Cr maybe ₹3,750 or some number. EBITDA margin where we are right now.

Guidance

Forward guidance and management's confidence

20% CAGR to ₹5,000 Cr by 2030

Medium

Reaffirmed from prior call. But H1 FY27 at ~15%, Q2 at +12% YoY suggests near-term execution risk.

FY27-28 guidance ₹3,750–4,000 Cr revenue

Medium

Implies 15–20% growth from FY27 base; Phase-2 contribution only from H2 FY28, so upside limited

Phase-2 revenue ₹1,000+ Cr at full capacity (12K MT)

Medium

Phase-2 capex ₹400–odd Cr, commercials Jun–Sep 2027, but full ramp into FY28–29

EBITDA margin sustain ~25%

High

Q2 delivered 27.48%, exceeding target. Structural OPM 26.3%. Mix benefit from new higher-value products.

Phase 2 & 3 combined: ₹1,000 Cr capex (Phase 1 ₹450 Cr completed)

High

Phase 2 expected ₹400–odd Cr (66K MT capacity), Phase 3 ₹400–425 Cr. Timeline: Phase 2 Jun–Sep 2027, Phase 3 pilot stage

Risks the call surfaced

Ranked by how much they should concern a holder

Revenue growth miss

High

H1 FY27 at ~15%, Q2 at +12% YoY. To hit 20% FY27 requires H2 at 25%+. Management defending guidance but no new order book data provided. Phase-2 revenue deferred to H2 FY28.

Regulatory approval delays

Medium

Fine Sciences revenue stuck at ₹68 Cr (FY26) vs ₹100 Cr target. Merger regulatory approvals pending; timeline vague ('next FY'). Capacity expansion limited by approvals.

Geopolitical and logistics risk

Medium

Extended West Asia war scenarios mentioned. Freight costs volatile. Though 70% of input from non-petroleum sources limits exposure.

FX and incentive dependency

Low

H1 benefited from ₹1.62 Cr state incentives (vs ₹9 Cr prior year, down 82%) and FX gains (large net exporter). Margin benefit may not sustain if dollar weakens.

Segment concentration (Pinene)

Medium

Pinene is largest segment; management withheld segment-level disclosure. Africa market and new applications are growth drivers, but no volume or % breakdown. Heavy dependence on pinene concentration.

Management

Score 7/10. Clear on financial metrics and roadmap (Phase 1-3 capex, 5K vision by 2030). Transparent on cash flow and balance sheet. Evasive on segment disclosure and near-term growth math. Met EBITDA and profitability targets; beat PAT guidance. Missed revenue growth guidance (12% vs 20%). Phase-1 on time; Phase-2 and Fine Sciences delayed. Track record mixed.

What to watch next
  • 1 · Q3 FY27 (Oct–Dec)

    New debottlenecking contracts ramp; Phase-1 capacity utilization target 85–90%

  • 2 · Q4 FY27 (Jan–Mar 2027)

    Significant volume growth from expanded capacity; ₹12–15 Cr remaining incentive inflow

  • 3 · Jun–Sep 2027

    Phase-2 commercial production begins; targeted ₹225 Cr JV revenue by FY27-28

Phase-2 ramp delayed to H2 FY28; regulatory approvals on Fine Sciences merger pending.

Informational and educational content only. Not investment advice.